Page last updated: 2024-12-11
crotarbital
Description
Research Excerpts
Clinical Trials
Roles
Classes
Pathways
Study Profile
Bioassays
Related Drugs
Related Conditions
Protein Interactions
Research Growth
Description
crotarbital: RN given refers to parent cpd without isomeric designation [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
Cross-References
| ID Source | ID |
|---|---|
| PubMed CID | 5364821 |
| SCHEMBL ID | 712976 |
| SCHEMBL ID | 2285746 |
| MeSH ID | M0040687 |
Synonyms (48)
| Synonym |
|---|
| ethyl(crotyl)barbiturate |
| nsc125735 |
| ethyl-crotyl-barbiturate |
| kalipnon |
| nsc-125735 |
| mepertan |
| barbituric acid, 5-(2-butenyl)-5-ethyl- |
| crotarbital |
| barotal |
| go 1046 |
| 2,6(1h,3h,5h)-pyrimidinetrione, 5-(2-butenyl)-5-ethyl- |
| calypnone |
| barotalum |
| kalypnetten |
| 1952-67-6 |
| 5-(2-butenyl)-5-ethylbarbituric acid |
| 5-ethyl-5-crotylbarbituric acid |
| kalypnon |
| crotylbarbital |
| crotylbarbitalum |
| 2,4,6(1h,3h,5h)-pyrimidinetrione, 5-(2-butenyl)-5-ethyl- |
| einecs 217-777-9 |
| nsc 125735 |
| ethyl (crotyl)barbiturate |
| 5-(2-butenyl)-5-ethyl-1h,3h,5h-pyrimidine-2,4,6-trione |
| 5-aethyl-5-crotylbarbitursaure [german] |
| 5-[(e)-but-2-enyl]-5-ethyl-1,3-diazinane-2,4,6-trione |
| 5-aethyl-5-crotylbarbitursaure |
| unii-sxw2hl5ju7 |
| sxw2hl5ju7 , |
| 2,4,6(1h,3h,5h)-pyrimidinetrione, 5-(2-butenyl)-5-ethyl-, (e)- |
| crotarbital [who-dd] |
| crotylbarbitone |
| 28360-89-6 |
| 5-crotyl-5-ethylbarbituric acid |
| 2,4,6(1h,3h,5h)-pyrimidinetrione, 5-(2-buten-1-yl)-5-ethyl- |
| crotarbitone |
| go-1046 |
| crotylbital |
| SCHEMBL712976 |
| KNMOHCLEINXVBG-HWKANZROSA-N |
| 5-[2-butenyl]-5-ethyl-2,4,6(1h,3h,5h)-pyrimidinetrione # |
| SCHEMBL2285746 |
| HY-101629 |
| CS-6573 |
| (e)-crotylbarbital |
| Q5189013 |
| AKOS040732215 |
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
Research
Studies (8)
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 7 (87.50) | 18.7374 |
| 1990's | 1 (12.50) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
Study Types
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 1 (10.00%) | 5.53% |
| Reviews | 0 (0.00%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 9 (90.00%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||